First-generation somatostatin ligand receptor treatment in a pregnant patient with a neuroendocrine tumor with liver metastases

• Main Authors: Nynne Emilie Hummelshøj, Gitte Dam, Lars Henning Pedersen, Astrid Hjelholt, Gerda Elisabeth Villadsen
• Format: Article
• Language: English
• Published: Bioscientifica 2021-10-01
• Series: Endocrinology, Diabetes & Metabolism Case Reports
• Online Access: https://edm.bioscientifica.com/view/journals/edm/2021/1/EDM21-0126.xml

This rare case describes the course of a pregnancy in a patient with a disseminated small intestinal neuroendocrine tumor. The patient received treatment with first-generation somatostatin ligand receptor (SLR) every 4 weeks and had stable disease for several years before her pregnancy. First-generation SLR treatment was initially paused after detection of the pregnancy. During pregnancy, the patient experienced moderate gastro-intestinal discomfort and fatigue, which was considered predominantly pregnancy related. However, since symptoms could be linked to the patient’s cancer, treatment was resumed after the first trimester. Chromogranin-A measurements remained stable throughout pregnancy and was paralleled by the absence of diarrhea and only minor flushing. She gave birth by elective caesarean section in week 37 to a healthy baby. Subsequent follow up imaging immediately after and 10 months postpartum showed no disease progression. The safety profile of SLR treatment during pregnancy in the context of disseminated neuroendocrine tumors (NET) is discussed.